ArticleJournal of ophthalmic & vision research2024
Pharmacological Treatment of Presbyopia Using Pilocarpine 1.25% Eye Drops.
Article in Journal of ophthalmic & vision research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluating Pilocarpine 1% Eye Drops in Presbyopia: A Triple-Blinded Randomized Trial.Journal of ophthalmology · 2026Article
- Pharmacological Modulation of Pupil Size in Presbyopia: Optical Modeling and Clinical Implications.Journal of clinical medicine · 2025Article
- New Sight for Old: Commentary On the Use of Pilocarpine for Presbyopia.Journal of ophthalmic & vision research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the efficiency and safety of pilocarpine eye drop 1.25% analogue (IR- Pilo) in comparison with its original brand-name drug (Vuity). Methods: In this non-randomized comparative study, 75 patients with presbyopia aged 40 to 60 years were enrolled. The right eyes of these patients received either IR-Pilo ( Results: The mean refractive error was stable, except for a small myopic shift in the Vuity group. There was no significant change in distance BCVA. Near vision improved significantly in both intervention groups ( Conclusion: IR-Pilo and Vuity eye drops had comparable results; both were effective and led to stable distance vision and improved near vision. Both ophthalmic drugs were safe and none of them were associated with significant adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.